Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 9/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 7/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470804 | 0.82 | CHEK1 (0.41) | CHEK1MAPTGAATHRBKMT2A | |
| SCHEMBL5478071 | 0.80 | LMNA (0.52) | CHEK1MAPTSMN1; SMN2KMT2ALMNA | |
| SCHEMBL5473339 | 0.78 | CHEK1 (0.55) | CHEK1KMT2AALDH1A1KDM4E | |
| SCHEMBL5480737 | 0.74 | CHEK1 (0.58) | CHEK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL5470116 | 0.72 | CHEK1 (0.50) | CHEK1MAPTGAASMN1; SMN2KMT2A | |
| SCHEMBL5470789 | 0.71 | CHEK1 (0.47) | CHEK1GAAKMT2AALDH1A1KDM4E | |
| SCHEMBL5473473 | 0.71 | CHEK1 (0.45) | CHEK1 | |
| SCHEMBL5465690 | 0.70 | CHEK1 (0.61) | CHEK1MAPTGAAPOLBKMT2A | |
| SCHEMBL5795825 | 0.68 | CHEK1 (0.44) | CHEK1MAPTGAAKMT2ALMNA | |
| SCHEMBL5465758 | 0.67 | CHEK1 (0.57) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | CHEK1 13/4885MAPT 2300/4885GAA 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.